Timothy Doyle, DO
Ophthalmology · Dover, DENPI 1700017902
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations.
Across 163 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$610
- Regeneron Healthcare Solutions, Inc.$482
- AbbVie$453
- Sun Pharmaceutical Industries Inc.$211
- Amgen$193
- Bausch & Lomb Americas Inc.$191
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,414100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 20 | $610 |
| Regeneron Healthcare Solutions, Inc. | 23 | $482 |
| AbbVie(2 entities) | 24 | $453 |
| Sun Pharmaceutical Industries Inc. | 8 | $211 |
| Amgen(2 entities) | 12 | $193 |
| Bausch & Lomb Americas Inc. | 10 | $191 |
| Genentech USA, Inc. | 15 | $183 |
| Novartis | 10 | $181 |
| Mallinckrodt Hospital Products Inc. | 5 | $146 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $146 |
| Astellas Pharma US Inc | 2 | $63 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $61 |
| Rxsight Inc | 2 | $50 |
| Dompe US, Inc. | 2 | $46 |
| Tarsus Pharmaceuticals, Inc. | 2 | $45 |
| Thea Pharma Inc. | 2 | $39 |
| Ivantis, Inc | 1 | $38 |
| Ocular Therapeutix, Inc. | 2 | $31 |
| Genentech, Inc. | 1 | $27 |
| Eyepoint US, Inc. | 1 | $24 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Coopervision Inc. | 1 | $22 |
| NEW World Medical,inc. | 1 | $21 |
| Vyera Pharmaceuticals, LLC | 1 | $20 |
| Omeros Corporation | 1 | $18 |
| GSK | 1 | $17 |
| Alimera Sciences, Inc. | 1 | $17 |
| Rayner Intraocular Lenses Limited | 1 | $15 |
| Sight Sciences, Inc. | 1 | $14 |
| Aerie Pharmaceuticals, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Centurion$129
How this compares
$3,414 in reported general payments places this provider in the 75th percentile of 49 ophthalmology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 98 | $60,930 |
| XiidraLifitegrast | 34 | $58,722 |
| Brimonidine Tartrate | 293 | $40,905 |
| RestasisCyclosporine | 27 | $35,724 |
| CombiganBrimonidine Tartrate/Timolol | 52 | $23,953 |
| IlevroNepafenac | 44 | $16,075 |
| Cyclosporine | 17 | $15,228 |
| Travoprost | 71 | $13,797 |
| Lotemax SmLoteprednol Etabonate | 59 | $13,320 |
| RocklatanNetarsudil Mesylat/Latanoprost | 23 | $13,087 |
| RhopressaNetarsudil Mesylate | 25 | $12,051 |
| Latanoprost | 579 | $11,746 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 657 | $10,291 |
| Prednisolone Acetate | 328 | $9,893 |
| BromsiteBromfenac Sodium | 33 | $8,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $453 | $128,687191 claims |
| Bausch & Lomb Americas Inc.Xiidra | $191 | $58,72234 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $13 | $25,13848 claims |
| NovartisIlevro | $181 | $16,07544 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $146 | $13,32059 claims |
| Sun Pharmaceutical Industries Inc.Bromsite | $211 | $8,46533 claims |
| AlconSimbrinza | $610 | $8,03223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 49 ophthalmology providers in Delaware.
Other ophthalmology in Dover
- David CreechDover$22K
- Bryan SeiffDover$9K
- David LuDover$5K
- Jeffrey MinkovitzWilmington$7K
- Heather DealyWilmington$6K
- Stewart SmithWilmington$6K
- Richard SherryWilmington$5K
- Karen RudoMilford$5K
- Scott FudembergRehoboth Beach$5K
- Michael BrosmanWilmington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.